Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ).
Cizzle Biotechnology Holdings PLC has announced the posting of its Annual General Meeting notice and the availability of its Annual Report and Financial Statements for 2024. The AGM is scheduled for June 30, 2025, in London. This announcement marks a routine corporate update, ensuring transparency and engagement with shareholders, which is crucial for maintaining investor confidence and supporting the company’s strategic initiatives in cancer diagnostics.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer focused on the early detection of cancer. The company has developed a non-invasive, cost-effective blood test using the CIZ1B biomarker, which is associated with early-stage lung cancer. Cizzle has entered into commercial royalty-bearing agreements to license its technology and collaborates with leading cancer care centers. The company was listed on the London Stock Exchange in May 2021.
Average Trading Volume: 1,277,986
Technical Sentiment Signal: Hold
Current Market Cap: £7.14M
Find detailed analytics on CIZ stock on TipRanks’ Stock Analysis page.